RT Journal Article
T1 Ru(II) and Ir(III) phenanthroline-based photosensitisers bearing o-carborane: PDT agents with boron carriers for potential BNCT
A1 Conway-Kenny, Robert
A1 Ferrer-Ugalde, Albert
A1 Careta, Oriol
A1 Cui, Xiaoneng
A1 Zhao, Jianzhang
A1 Nogués, Carme
A1 Núñez, Rosario
A1 Cabrera González, Justo Enrique
A1 Draper, Sylvia M.
AB Four novel transition metal-carborane photosensitisers were prepared by Sonogashira cross-coupling of 1-(4-ethynylbenzyl)-2-methyl-o-carborane (A-CB) with halogenated Ru(II)- or Ir(III)-phenanthroline complexes. The resulting boron-rich complexes with one (RuCB and IrCB) or two carborane cages (RuCB2 and IrCB2) were spectroscopically characterised, and their photophysical properties investigated. RuCB displayed the most attractive photophysical properties in solution (λem 635 nm, τT 2.53 μs, and φp 20.4%). Nanosecond time-resolved transient absorption studies were used to explore the 3MLCT nature of the triplet excited states, and the highest singlet oxygen quantum yields (ΦΔ) were obtained for the mono-carborane-phenanthroline complexes (RuCB: 52% and IrCB: 25%). None of the complexes produce dark toxicity in SKBR-3 cells after incubation under photodynamic therapy (PDT) conditions. Remarkably, mono-carboranes RuCB and IrCB were the best internalised by the SKBR-3 cells, demonstrating the first examples of tris-bidentate transition metal-carborane complexes acting as triplet photosensitisers for PDT with a high photoactivity; RuCB or IrCB killed ∼50% of SKBR-3 cells at 10 μM after irradiation. Therefore, the high-boron content and the photoactive properties of these photosensitisers make them potential candidates as dual anti-cancer agents for PDT and Boron Neutron Capture Therapy (BNCT).
PB Royal Society of Chemistry
YR 2021
FD 2021-05-10
LK https://hdl.handle.net/20.500.14352/98286
UL https://hdl.handle.net/20.500.14352/98286
LA eng
NO Science Foundation Ireland
NO Ministerio de Ciencia, Innovación y Universidades(España)
NO Agencia Estatal de Investigación
NO Generalitat de Cataluña
DS Docta Complutense
RD 6 oct 2024